No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HTGC240517P20000
- 0.67
- -0.08-10.67%
15min DelayClose May 9 16:00 ET
0.67High0.67Low
0.67Open0.75Pre Close2 Volume134 Open Interest20.00Strike Price134.00Turnover54.56%IV-2.82%PremiumMay 17, 2024Expiry Date0.14Intrinsic Value100Multiplier7DDays to Expiry0.53Time Value100Contract SizeAmericanOptions Type-0.5139Delta0.2503Gamma28.37Leverage Ratio-0.0401Theta-0.0021Rho-14.58Eff Leverage0.0117Vega
Intraday
- 5D
- 1D
News
Hercules Capital To Go Ex-Dividend On May 13th, 2024 With 0.4 USD Dividend Per Share And 0.08 USD Special Dividend Per Share
May 10th - $Hercules Capital(HTGC.US)$ is trading ex-dividend on May 13th, 2024. Shareholders of record on May 14th, 2024 will receive 0.4 USD dividend per share and 0.08 USD special dividend per
Verona Pharma Signs Financing Agreements for Up to $650 Million
Verona Pharma (VRNA) said Thursday it signed deals providing up to $650 million in financing from funds managed by Oaktree Capital Management and OMERS Life Sciences. The financing consists of up to $
X4 Pharma Gains on New $125 Financing
Express News | Electric Hydrogen: $100 Mln Credit Facility From HSBC, J.p. Morgan, Stifel Bank and Hercules Capital
Express News | Verona Pharma PLC - Cash Runway Extended Beyond 2026
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Comments
Despite a cautious outlook for the asset management sector, Love advocates for Blackstone and Hercules Capital due to the potential growth of alternative assets and private credit. Predicting an 'Alternatives Era', he expects a significant rise in their share of investable assets globally.
The Stocks of Stockpickers Rebounded in Late 2023. It Might Not Continue. -- Barrons.comHercules Capital's low P/E is attributed to expectations of lower future earnings than the broader market and the reduced pay by investors expecting limited future growth. Factors such as lower than market growth forecast and current low P/E are inhibiting share price rise.
1
Pre-Market Stock Movers
Gapping up
$NVIDIA(NVDA.US$ stock rose 0.4%, adding more gains after the chipmaker recorded its highest-ever closing price on Tuesday, as it has become the focal point of a recent surge in enthusiasm around the applications of generative artificial intelligence.
Gapping down
$HP Inc(HPQ.US$ stock fell 8.3% after the information technology company tempered expectations for annual profit, as it g...
Gapping up
$NVIDIA(NVDA.US$ stock rose 0.4%, adding more gains after the chipmaker recorded its highest-ever closing price on Tuesday, as it has become the focal point of a recent surge in enthusiasm around the applications of generative artificial intelligence.
Gapping down
$HP Inc(HPQ.US$ stock fell 8.3% after the information technology company tempered expectations for annual profit, as it g...
17
2
Upgrades
• $American Airlines(AAL.US$ : JP Morgan Upgrades to Neutral From Underweight - PT $26 (from $18)
• $The AZEK(AZEK.US$ : Citigroup Upgrades to Buy from Neutral - PT $30 (from $36)
• $Boston Properties Inc(BXP.US$ : Mizuho Upgrades to Buy from Neutral - PT $135 (from $120)
• $Dow Inc(DOW.US$ : Citigroup Upgrades To Buy From Neutral - PT $82 (from $70)
• $The Kroger(KR.US$ : Exane Upgrades to Neutral from Underperform - PT $60
• $Milestone Pharmaceuticals(MIST.US$ : Piper S...
• $American Airlines(AAL.US$ : JP Morgan Upgrades to Neutral From Underweight - PT $26 (from $18)
• $The AZEK(AZEK.US$ : Citigroup Upgrades to Buy from Neutral - PT $30 (from $36)
• $Boston Properties Inc(BXP.US$ : Mizuho Upgrades to Buy from Neutral - PT $135 (from $120)
• $Dow Inc(DOW.US$ : Citigroup Upgrades To Buy From Neutral - PT $82 (from $70)
• $The Kroger(KR.US$ : Exane Upgrades to Neutral from Underperform - PT $60
• $Milestone Pharmaceuticals(MIST.US$ : Piper S...
16
Read more